T. Rowe Price Associates
ADMA icon

T. Rowe Price Associates’s ADMA Biologics ADMA Stock Holding History

T. Rowe Price Associates’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20M Buy
2,216,285
+55,726
+3% +$879K ﹤0.01% 1037
2025
Q4 		$39.4M Buy
2,160,559
+4,897
+0.2% +$82.5K ﹤0.01% 879
2025
Q3 		$31.6M Buy
2,155,662
+16,422
+0.8% +$281K ﹤0.01% 936
2025
Q2 		$39M Buy
2,139,240
+28,309
+1% +$577K ﹤0.01% 794
2025
Q1 		$41.9M Buy
2,110,931
+10,293
+0.5% +$178K 0.01% 769
2024
Q4 		$36M Buy
2,100,638
+504
+0% +$9.48K ﹤0.01% 854
2024
Q3 		$42M Buy
2,100,134
+23,806
+1% +$370K ﹤0.01% 806
2024
Q2 		$23.2M Buy
2,076,328
+2,015,404
+3,308% +$16.9M ﹤0.01% 920
2024
Q1 		$403K Buy
60,924
+7,450
+14% +$40.7K ﹤0.01% 2294
2023
Q4 		$242K Buy
53,474
+5,506
+11% +$20.4K ﹤0.01% 2466
2023
Q3 		$172K Buy
47,968
+6,101
+15% +$23.5K ﹤0.01% 2549
2023
Q2 		$155K Buy
41,867
+2,118
+5% +$7.85K ﹤0.01% 2595
2023
Q1 		$132K Buy
39,749
+7,920
+25% +$27.4K ﹤0.01% 2630
2022
Q4 		$123K Buy
31,829
+2,986
+10% +$9.21K ﹤0.01% 2674
2022
Q3 		$71K Buy
28,843
+11,109
+63% +$26.7K ﹤0.01% 2787
2022
Q2 		$35K Buy
+17,734
New +$34.9K ﹤0.01% 2896

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

T. Rowe Price Associates's ADMA Position: Q1 2026 in Review

T. Rowe Price Associates increased its ADMA Biologics (ADMA) stake by 2.6% in Q1 2026, buying an estimated $879K and bringing the position to 2,216,285 shares worth $20M. The position accounts for ﹤0.01% of the portfolio, ranked #1037.

T. Rowe Price Associates first reported a position in ADMA in Q2 2022 and has held it in 16 quarters since. The position peaked at $42M in Q3 2024. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • T. Rowe Price Associates held 2,216,285 shares of ADMA Biologics worth $20M as of Q1 2026.
  • T. Rowe Price Associates bought 55,726 ADMA Biologics shares in Q1 2026, an estimated $879K.
  • ADMA Biologics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1037 holding.
  • T. Rowe Price Associates first reported a position in ADMA Biologics in Q2 2022 and has held it in 16 quarters since.
  • T. Rowe Price Associates's ADMA Biologics position peaked at $42M in Q3 2024.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.